Myocardial oxygen consumption reduction (MVO2 reduction)

Myocardial oxygen consumption (MVO2) reduction is a physiological effect and a primary therapeutic objective in cardiology rather than a single molecular target. It represents a decrease in the metabolic demand of the heart muscle, which is dictated by three major determinants: heart rate, contractility, and ventricular wall stress (defined by preload and afterload). In clinical conditions such as stable angina or acute coronary syndromes, myocardial ischemia occurs when oxygen demand exceeds supply; therefore, reducing MVO2 is critical to restoring this balance and preventing tissue necrosis. This physiological state is achieved through the pharmacological modulation of various actual molecular targets, including the Beta-1 adrenergic receptor, L-type calcium channels, and Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. By slowing the heart rate and reducing the force of contraction, medications like beta-blockers and calcium channel blockers effectively lower the cardiac workload. Additionally, nitrates reduce MVO2 primarily by decreasing preload through peripheral venodilation, further illustrating that MVO2 reduction is a systemic hemodynamic and metabolic outcome.

Other names

Decreased myocardial oxygen demandReduction in cardiac oxygen consumptionLowering of MVO2Myocardial oxygen demand reduction

Reduction of heart rate (negative chronotropy), reduction of myocardial contractility (negative inotropy), reduction of ventricular wall stress through decreased preload (venodilation) or decreased afterload (arterial vasodilation), and inhibition of late sodium currents.